Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button

FAQs

FAQs
Preclinical Safety Characteristics of siRNA Drugs
The biological effects of silencing of target mRNA may be present, but it is not easy to see other effects
Learn more
What are the Advantages and Disadvantages of Nucleic Acid Drugs?
Advantages: Short development cycle, fast target screening; A wide range of treatment areas; Resistant to drug resistance; Long-lasting effect; High success rate of R&D
Learn more
What are Polymorphs?
In July 2007, the United States FDA issued the technical guidelines for generic drug crystal research, pointing out that polycrystalline polymorph includes crystal or amorphous, as well as solvates and hydrates, which are described as follows:
Learn more
Why does the API for Crystal Structures Screening Require Sample Purity?
​Impurities can affect their dynamic stability in solution and suspension by affecting nucleation and growth rates.
Learn more
Can Medicilon Complete Preclinical DMPK Services?
Can Medicilon complete preclinical DMPK services?
Learn more
What are the Preclinical PK Data Analysis Methods?
What are the preclinical PK data analysis methods?
Learn more
What In Vivo PK Tests Should be Completed Before IND Filing in China?
What In Vivo PK tests should be completed before IND filing in China?
Learn more
What Should be Done for Significant AUC Differences In Vivo PK Tests in Animals?
(1) The reasons for large differences can be summarized as poor solubility of the compound or solubility being subject to significant fluctuations in digestive tract pH. (2) Improve the formulation and adjust the digestive tract PH value.
Learn more
What Should Explain Bioavailability F > 100% in Animals' In Vivo PK Test?
(1) Dose deviation due to administration error. (2) Non-linear PK. (3) High bioavailability and individual variability in the DMPK properties of the drug, with IV and PO, given to different groups of animals.
Learn more
What is the Explanation for the Clearance (CL) > Hepatic Blood Flow (Qh) in the In Vivo PK Test in Animals?
What is the explanation for the clearance (CL) > hepatic blood flow (Qh) in the in vivo PK test in animals?
Learn more